BVF Inc’s Karyopharm Therapeutics KPTI Stock Holding History

BVF Inc’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-23,684	Closed	-$2.13M	–	60
2019 Q2	$2.13M	Buy	+23,684	New	+$1.9M	0.23%	51

Other funds holding KPTI

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BVF Inc's KPTI Position: Q3 2019 in Review

BVF Inc sold out of Karyopharm Therapeutics (KPTI) in Q3 2019, closing a stake of 23,684 shares — an estimated $2.13M sold.

BVF Inc first reported a position in KPTI in Q2 2019 and held it in 1 quarter. The position peaked at $2.13M in Q2 2019. 106 funds tracked by Wall St. Rank hold KPTI as of Q3 2019.

BVF Inc reported no remaining Karyopharm Therapeutics position as of Q3 2019 after selling out during the quarter.
BVF Inc sold 23,684 Karyopharm Therapeutics shares in Q3 2019, an estimated $2.13M.
BVF Inc first reported a position in Karyopharm Therapeutics in Q2 2019 and held it in 1 quarter.
BVF Inc's Karyopharm Therapeutics position peaked at $2.13M in Q2 2019.
106 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q3 2019.

Based on BVF Inc's 13F filing for Q3 2019, filed 14 Nov 2019.